circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Note that virtually everything that happened in seasons 7-9 of Roseanne—other than Harris' birth—has been retconned out of existence in the show's universe, and there is no reason to assume that the date of Harris' birth is not affected by this retcon.
=== Depression === Dezocine shows antidepressant-like effects in animals. Its antidepressant-like effects in animals appear to be dependent on activation of serotonin 5-HT1A receptors and inhibition of κ-opioid receptors (KORs) but not on activation of the μ-opioid receptor. A clinical trial found that dezocine added to sufentanil for postoperative analgesia significantly reduced depressive symptoms in people undergoing colorectal cancer surgery relative to sufentanil alone. There is a case report of a single incidental dose of dezocine resulting in rapid and sustained improvement in depression, anhedonia, and motivational deficits in a woman with treatment-resistant depression. On the basis of the preceding findings, there is interest in dezocine as a potential antidepressant in the treatment of depression, for instance in people with opioid use disorder.
Freeze-drying, also known as freeze-casting or ice-templating, offers an alternative to the high temperature and high-pressure requirements of supercritical drying. Additionally, freeze-drying offers more control of the solid structure development by controlling the ice crystal growth during freezing. In this method, a colloidal dispersion of the aerogel precursors is frozen, with the liquid component freezing into different morphologies depending on a variety of factors such as the precursor concentration, type of liquid, temperature of freezing, and freezing container. As this liquid freezes, the solid precursor molecules are forced into the spaces between the growing crystals. Once completely frozen, the frozen liquid is sublimed into a gas through lyophilization, which removes much of the capillary forces, as was observed in supercritical drying. Though typically classified as a "cryogel", aerogels produced through freeze-drying often experience some shrinkage and cracking while also producing a non-homogenous aerogel framework. This often leads to freeze-drying being used for the creation of aerogel powders or as a framework for composite aerogels.
P. Saraswathy, A.C. Dey, S.K. Sarkar, C. Kothalkar, P. Naskar, G. Arjun, S.S. Arora, A.K. Kohli, V. Meera, V. Venugopal and N.Ramamoorthy (2007). "99mTc generators for clinical use based on zirconium molybdate gel and (n, gamma) produced 99 Mo: Indian experience in the development and deployment of indigenous technology and processing facilities" (PDF). Proceedings of the 2007 International RERTR Meeting.{{cite journal}}: CS1 maint: multiple names: authors list (link) Iturralde MP (1 December 1996). "Molybdenum-99 production in South Africa". European Journal of Nuclear Medicine. 23 (12): 1681–1687. doi:10.1007/BF01249633. S2CID 28154691. Hansell C (1 July 2008). "Nuclear Medicine's Double Hazard: Imperiled Treatment and the Risk of Terrorism" (PDF). The Nonproliferation Review. 15 (2): 185–208. doi:10.1080/10736700802117270. S2CID 8559456. Archived from the original (PDF) on 18 July 2013. Retrieved 24 May 2012.
Non-diabetics' beta cells routinely and automatically manage this by continual glucose level monitoring and insulin release. All such decisions by a diabetic must be based on experience and training (i.e., at the direction of a physician, PA, or in some places a specialist diabetic educator) and, further, specifically based on the individual experience of the person. But it is not straightforward and should never be done by habit or routine. With some care however, it can be done reasonably well in clinical practice. For example, some people with diabetes require more insulin after drinking skim milk than they do after taking an equivalent amount of fat, protein, carbohydrate, and fluid in some other form. Their particular reaction to skimmed milk is different from other people with diabetes, but the same amount of whole milk is likely to cause a still different reaction even in that person. Whole milk contains considerable fat while skimmed milk has much less. It is a continual balancing act for all people with diabetes, especially for those taking insulin. People with insulin-dependent diabetes typically require some base level of insulin (basal insulin), as well as short-acting insulin to cover meals (bolus also known as mealtime or prandial insulin). Maintaining the basal rate and the bolus rate is a continuous balancing act that people with insulin-dependent diabetes must manage each day.
Sources: en.wikipedia.org
=== Structure === It is an organic compound, associated with the class of L-alpha-amino acids. These compounds have the L-configuration of the alpha carbon atom. Quisqualic acid contains, in its structure a five membered, planar, conjugated, aromatic heterocyclic system, consisting of one oxygen atom and two nitrogen atoms at position 2 and 4 of the oxadiazole ring. The 1,2,4–oxadiazole ring structure is present in many natural products of pharmacological importance. Quisqualic acid, which is extracted from the seeds of Quisqualis indica, is a strong antagonist of AMPA receptors.
Le Havre appears in several literary works as a point of departure to America: in the 18th century, Father Prevost embarked Manon Lescaut and Des Grieux for French Louisiana. Fanny Loviot departed from Le Havre in 1852, as an emigrant to San Francisco and points further west, and recounted her adventures in Les pirates chinois (A Lady's Captivity among Chinese Pirates in the Chinese Seas, 1858). In the 19th century, Le Havre was the setting for several French novels: Honoré de Balzac described the failure of a Le Havre merchant family in Modeste Mignon. Later, the Norman writer Guy de Maupassant located several of his works at Le Havre such as Au muséum d'histoire naturelle (At the Museum of Natural History) a text published in Le Gaulois on 23 March 1881 and again in Pierre et Jean. Alphonse Allais located his intrigues at Le Havre too. La Bête humaine (The Human Beast) by Émile Zola evokes the world of the railway and runs along the Paris–Le Havre railway. Streets, buildings, and public places in Le Havre pay tribute to other famous Le Havre people from this period: the writer Casimir Delavigne (1793–1843) has a street named after him and a statue in front of the palace of justice alongside another man of letters, Bernardin de Saint-Pierre (1737–1814). In the 20th century, Henry Miller located part of the action in Le Havre in his masterpiece Tropic of Cancer, published in 1934. Bouville was the commune where the writer lived who wrote his diary in La Nausée (The Nausea) (1938) by Jean-Paul Sartre who was inspired by Le Havre city where he wrote his first novel.
Cycling extract is a cell-free system derived from Xenopus eggs that autonomously undergoes repeated S phase and M phase cycles. It is prepared by artificially inducing intracellular responses that mimic fertilization, typically through calcium ionophore treatment or electrical stimulation of unfertilized eggs, followed by mechanical crushing of the eggs. This extract has been instrumental in elucidating fundamental mechanisms of cell cycle regulation. For example, it revealed that entry into M phase depends on the translation of cyclin B, which in turn activates maturation promoting factor (MPF). Cycling extracts are primarily used to study the regulation of cell cycle progression.
He progressed to the quarterfinals after winning over Jaume Munar of Spain, Tomáš Macháč of Czech Republic, and Alexei Popyrin of Australia, all in straight sets. He was defeated in the quarterfinals by eventual bronze medalist Lorenzo Musetti of Italy in straight sets. In the American hard court swing, Zverev reached the quarterfinals in Montréal, losing to Sebastian Korda in three sets. He went on to defend his semifinal points in Cincinnati, losing to Jannik Sinner in an attritive three-set match. At the US Open, he reached the quarterfinals without facing a seeded opponent, with wins over lucky loser Maximilian Marterer, wildcard Alexandre Müller, Tomás Martín Etcheverry and Brandon Nakashima — his 450th career win. With that milestone, he became the second player born in the 1990s, after Grigor Dimitrov, to reach 450 ATP wins. With the win, he qualified for his seventh appearance at the 2024 ATP Finals. Zverev lost in the quarterfinals to Taylor Fritz. At the Paris Masters, Zverev defeated Tallon Griekspoor, Arthur Fils, and Stefanos Tsitsipas to set up a semifinal clash with former champion Holger Rune. He won the match in straight sets to reach the final for the second time at this event. Zverev defeated home crowd favorite Ugo Humbert in the final to clinch his second Masters title of the season and the world No. 2 ranking. Zverev won all three of his group matches at the ATP Finals to reach the semifinals, where he lost to Taylor Fritz in a deciding set tie-break.
Sources: en.wikipedia.org
=== Silicon batteries === The company started promoting its silicon-graphite-electrode batteries in 2019 and ceased development of its germanium-based batteries in 2020. The company sent germanium sample batteries to manufacturers in place of silicon sample batteries. The company's CEO said the germanium batteries were only developed as proof-of-concept, were only meant to be sold in small quantities, and that they were never released because they weren't sufficiently differentiated from the rest of the market. Group14 Technologies has developed silicon nanoparticles called SCC55 which allow lithium-silicon batteries to charge from 10% to 80% state-of-charge in 10 minutes. StoreDot tested the material for use in their silicon batteries. The company was looking in 2023 for suppliers capable of manufacturing thousands of tonnes of this material, which is critical for their business. The battery cells have a sponge-like carbon electrode imbued with silicon nanoparticles that react with the lithium ions, keeping the silicon's expansion within the carbon "sponge".
A 4th period, also described as "The third style" receives strong influence from Chinese painting, a result of the artistic activity and expansion of the Tang dynasty. The civilization of Kucha, with the whole Tarim Basin from Turfan to Khotan, fell to the Chinese punitive invasion of 648 CE, putting an end to the Indo-Iranian styles of Kucha. Ashina She'er, the East Turkic general leading the Tang dynasty expeditionary corps, ordered the execution of eleven thousand Kuchean inhabitants by decapitation. It was recorded that "he destroyed five great towns and with them many myriads of men and women... the lands of the west were seized with terror." Two caves at Kizil have art of the Tang period: cave 43 and cave 229. In nearby Kumtura and in Turfan, Chinese styles now prevailed. In 670 CE, the Tibetan Empire conquered most of the Tarim Basin, including Khotan, Kucha, Karashahr and Kashgar, which they kept until the Chinese took back the control of the area in 692. In 753 CE, the northern part of the Tarim Basin was taken over by the Turks of the Uyghur Khaganate, based in Turfan. A new Tibetan conquest took place in 790 CE. By 900 CE, the area was under Muslim domination.
Conditions with normally functioning neutrophils – hereditary neutrophilia, chronic idiopathic neutrophilia Pelger–Huët anomaly Down syndrome Leukocyte adhesion deficiency Familial cold urticaria Leukemia (chronic myelogenous (CML)) and other myeloproliferative disorders Surgical removal of spleen Secondary causes
=== Bone scan === The nuclear medicine technique commonly called the bone scan usually uses 99mTc. It is not to be confused with the "bone density scan", DEXA, which is a low-exposure X-ray test measuring bone density to look for osteoporosis and other diseases where bones lose mass without rebuilding activity. The nuclear medicine technique is sensitive to areas of unusual bone rebuilding activity, since the radiopharmaceutical is taken up by osteoblast cells which build bone. The technique therefore is sensitive to fractures and bone reaction to bone tumors, including metastases. For a bone scan, the patient is injected with a small amount of radioactive material, such as 700–1,100 MBq (19–30 mCi) of 99mTc-medronic acid and then scanned with a gamma camera. Medronic acid is a phosphate derivative which can exchange places with bone phosphate in regions of active bone growth, so anchoring the radioisotope to that specific region. To view small lesions (less than 1 centimetre (0.39 in)) especially in the spine, the SPECT imaging technique may be required, but in the United States most insurance companies require separate authorization for SPECT imaging.
== Safety == No major serious adverse events have been reported; however, long-term cardiovascular safety has not been established. Concerns have been raised regarding increase in serum creatinine with the use of saroglitazar, initially noted in a meta-analysis published by Dutta et al. In another randomized controlled trial published by Gawrieh et al., a mild but significant increase in serum creatinine was noted with 16 weeks use of saroglitazar at 4mg/day dose.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.